Efficacy of pramipexole treatment and methylphenidate for attention deficit hyperactivity disorder

Efficacy of pramipexole treatment and methylphenidate in children with attention deficit hyperactivity disorder, compared with placebo and methylphenidate

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100520003979N7

Enrollment

Registered

2018-06-11

Start date

2018-05-22

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

attention deficit hyperactivity disorder. Disturbance of activity and attention

Interventions

Intervention 1: Intervention group: children will be treated with Methylphenidate and Pramipexole during 12 weeks. The starting dose of methylphenidate will be considered to be 0.3mg / kg in two divid

Eligibility

Sex/Gender

All

Age

6 Years to 12 Years

Inclusion criteria

Inclusion criteria: Age of children aged 6 to 12 years Having diagnostic criteria based on IV-IRDSM and Conners test

Exclusion criteria

Exclusion criteria: The presence of other medical conditions (heart problem, kidney failure, epilepsy, etc.) The presence of other serious psychiatric disorders such as mood disorders, penetrating disorders, and The presence of symptoms of mental disability a history of seizure

Design outcomes

Primary

Measure	Time frame
Attention Deficit Hyperactivity Disorder. Timepoint: Befor intervention- the end of second, fourth and sixth,eighth, tenth,twelfth weeks of the study. Method of measurement: The Conner's parent rating scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZohre Khozoeii Ashekzari

Ahvaz University of Medical Sciences

z.khozuey@yahoo.com+98 61 3374 3038

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026